Oxford Biomedica (LON:OXB) Stock Price Down 14.6% – What’s Next?

Oxford Biomedica plc (LON:OXB) shares dropped 14.6% during trading on Friday . The stock traded as low as GBX 441.50 and last traded at GBX 505. Approximately 6,604,510 shares changed hands during mid-day trading, an increase of 638% from the average session volume of 895,491 shares. The stock had previously closed at GBX 591.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Royal Bank Of Canada decreased their target price on Oxford Biomedica from GBX 1,170 to GBX 1,140 and set an “outperform” rating for the company in a research report on Wednesday, June 24th. Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 8.27 price target on shares of Oxford Biomedica in a research note on Tuesday, June 2nd. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Oxford Biomedica presently has an average rating of “Buy” and an average price target of GBX 669.85.

Oxford Biomedica Stock Performance

The company has a debt-to-equity ratio of 162.16, a quick ratio of 1.67 and a current ratio of 2.20. The business’s 50-day moving average is GBX 604.33 and its 200-day moving average is GBX 650.49. The company has a market capitalization of £611.24 million, a PE ratio of -18.76 and a beta of 1.12.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.